We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+17.76%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$92.3M
Cap. Flow
+$98.3M
Cap. Flow %
25.91%
Top 10 Hldgs %
63.93%
Holding
34
New
5
Increased
14
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$35.7M
2
MRUS
Merus
MRUS
+$15.4M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$12.3M
4
TNYA icon
Tenaya Therapeutics
TNYA
+$11M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.9M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$14.9M
2
MGNX icon
MacroGenics
MGNX
+$10.6M
3
EPIX
ESSA Pharma
EPIX
+$8.05M
4
MRSN
Mersana Therapeutics
MRSN
+$5.83M
5
CLDX icon
Celldex Therapeutics
CLDX
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 92.47%
2 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$44.7M 11.78%
2,750,137
+1,001,896
+57% +$10.9M
ACRS icon
2
Aclaris Therapeutics
ACRS
$730M
$39.4M 10.39%
2,190,291
+521,304
+31% +$8.36M
CYTK icon
3
Cytokinetics
CYTK
$11B
$28.5M 7.51%
796,578
+92,261
+13% +$2.72M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$26.1M 6.87%
+1,292,251
New +$35.7M
CCCC icon
5
C4 Therapeutics
CCCC
$376M
$21.5M 5.67%
481,094
– –
KURA icon
6
Kura Oncology
KURA
$922M
$18.7M 4.94%
999,433
+377,940
+61% +$7.12M
CELC icon
7
Celcuity
CELC
$4.03B
$16.6M 4.37%
920,464
+49,497
+6% +$1.05M
COGT icon
8
Cogent Biosciences
COGT
$6.79B
$16.1M 4.24%
1,912,511
+544,929
+40% +$4.18M
MRUS
9
DELISTED
Merus
MRUS
$15.8M 4.17%
+718,136
New +$15.4M
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$15.2M 4.01%
4,169,896
+640,431
+18% +$2.52M
STSA
11
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$14.5M 3.83%
3,118,761
+22,032
+0.7% +$117K
VTGN icon
12
VistaGen Therapeutics
VTGN
$9.29M
$14M 3.7%
170,784
+59,740
+54% +$5.19M
CLDX icon
13
Celldex Therapeutics
CLDX
$2.77B
$13.4M 3.53%
248,207
-75,230
-23% -$3.53M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.13B
$11M 2.9%
667,674
+481,269
+258% +$7.06M
TNYA icon
15
Tenaya Therapeutics
TNYA
$168M
$10.6M 2.8%
+513,930
New +$11M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.23B
$8.95M 2.36%
+362,869
New +$8.55M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.32B
$8.85M 2.33%
579,432
+253,096
+78% +$4.4M
PTGX icon
18
Protagonist Therapeutics
PTGX
$8.75B
$8.83M 2.33%
498,079
+287,479
+137% +$12.3M
KRON
19
DELISTED
Kronos Bio
KRON
$6.26M 1.65%
298,839
– –
RVMD icon
20
Revolution Medicines
RVMD
$40.2B
$6.22M 1.64%
+226,228
New +$6.58M
GNCA
21
DELISTED
Genocea Biosciences, Inc.
GNCA
$5.91M 1.56%
3,079,756
+150,309
+5% +$296K
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$5.45M 1.44%
312,553
+85,882
+38% +$1.74M
DYN icon
23
Dyne Therapeutics
DYN
$4.04B
$4.96M 1.31%
305,125
– –
MREO
24
Mereo BioPharma
MREO
$45.9M
$4.78M 1.26%
1,972,958
-86,771
-4% -$230K
PMVP icon
25
PMV Pharmaceuticals
PMVP
$66.1M
$3.73M 0.98%
125,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Commodore Capital held 34 positions worth $379M, up 32% from $287M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Commodore Capital deployed $98.3M of net new capital in Q3 2021, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 1,292,251 shares worth $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Celldex Therapeutics, an estimated $3.53M trimmed.

  • Commodore Capital's largest Q3 2021 buy was Dicerna Pharmaceuticals, Inc.: 1,292,251 shares worth $26.1M.
  • Commodore Capital added most to Protagonist Therapeutics in Q3 2021, an estimated $12.3M increase.
  • Commodore Capital's biggest Q3 2021 reduction was Celldex Therapeutics, cutting an estimated $3.53M.
  • Commodore Capital fully exited Constellation Pharmaceuticals, Inc. in Q3 2021, selling an estimated $14.9M.
  • Commodore Capital's ten largest holdings make up 64% of its $379M portfolio in Q3 2021.
  • Commodore Capital opened 5 new positions and closed 5 in Q3 2021.
  • Commodore Capital's portfolio value rose 32% quarter-over-quarter to $379M.

Based on Commodore Capital's 13F filing for Q3 2021, filed 15 Nov 2021.